Turning Defense into Offense: Defensin Mimetics as Novel Antibiotics Targeting Lipid II

English version České info

We have previously reported on the functional interaction of Lipid II with human alpha-defensins, a class of antimicrobial peptides. Lipid II is an essential precursor for bacterial cell wall biosynthesis and an ideal and validated target for natural antibiotic compounds. Using a combination of structural, functional and in silico analyses, we present here the molecular basis for defensin-Lipid II binding. Based on the complex of Lipid II with Human Neutrophil peptide-1, we could identify and characterize chemically diverse low-molecular weight compounds that mimic the interactions between HNP-1 and Lipid II. Lead compound BAS00127538 was further characterized structurally and functionally; it specifically interacts with the N-acetyl muramic acid moiety and isoprenyl tail of Lipid II, targets cell wall synthesis and was protective in an in vivo model for sepsis. For the first time, we have identified and characterized low molecular weight synthetic compounds that target Lipid II with high specificity and affinity. Optimization of these compounds may allow for their development as novel, next generation therapeutic agents for the treatment of Gram-positive pathogenic infections.

Vyšlo v časopise: Turning Defense into Offense: Defensin Mimetics as Novel Antibiotics Targeting Lipid II. PLoS Pathog 9(11): e32767. doi:10.1371/journal.ppat.1003732
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1003732

Souhrn

Zdroje

1. GoldHS, MoelleringRCJr (1996) Antimicrobial-drug resistance. N Engl J Med 335: 1445–1453.

2. SwartzMN (1994) Hospital-acquired infections: diseases with increasingly limited therapies. Proc Natl Acad Sci U S A 91: 2420–2427.

3. LabischinskiH, GoodellEW, GoodellA, HochbergML (1991) Direct proof of a “more-than-single-layered” peptidoglycan architecture of Escherichia coli W7: a neutron small-angle scattering study. J Bacteriol 173: 751–756.

4. McCloskeyMA, TroyFA (1980) Paramagnetic isoprenoid carrier lipids. 2. Dispersion and dynamics in lipid membranes. Biochemistry 19: 2061–2066.

5. McCaffertyDG, CudicP, FrankelBA, BarkallahS, KrugerRG, et al. (2002) Chemistry and biology of the ramoplanin family of peptide antibiotics. Biopolymers 66: 261–284.

6. BreukinkE, de KruijffB (2006) Lipid II as a target for antibiotics. Nat Rev Drug Discov 5: 321–332.

7. BauerR, DicksLM (2005) Mode of action of lipid II-targeting lantibiotics. Int J Food Microbiol 101: 201–216.

8. BrotzH, BierbaumG, ReynoldsPE, SahlHG (1997) The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation. Eur J Biochem 246: 193–199.

9. McCaffertyDG, CudicP, YuMK, BehennaDC, KrugerR (1999) Synergy and duality in peptide antibiotic mechanisms. Curr Opin Chem Biol 3: 672–680.

10. RuzinA, SinghG, SeverinA, YangY, DushinRG, et al. (2004) Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant gram-positive bacteria. Antimicrob Agents Chemother 48: 728–738.

11. MakiH, MiuraK, YamanoY (2001) Katanosin B and plusbacin A(3), inhibitors of peptidoglycan synthesis in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 45: 1823–1827.

12. BevinsCL (2006) Paneth cell defensins: key effector molecules of innate immunity. Biochem Soc Trans 34: 263–266.

13. GanzT (2003) Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 3: 710–720.

14. LehrerRI (2004) Primate defensins. Nat Rev Microbiol 2: 727–738.

15. SelstedME, OuelletteAJ (2005) Mammalian defensins in the antimicrobial immune response. Nat Immunol 6: 551–557.

16. BrogdenKA, AckermannM, McCrayPBJr, TackBF (2003) Antimicrobial peptides in animals and their role in host defences. Int J Antimicrob Agents 22: 465–478.

17. de LeeuwE, LiC, ZengP, Diepeveen-de BuinM, LuWY, et al. (2010) Functional interaction of human neutrophil peptide-1 with the cell wall precursor lipid II. FEBS Lett 584: 1543–1548.

18. SchneiderT, KruseT, WimmerR, WiedemannI, SassV, et al. (2010) Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. Science 328: 1168–1172.

19. SassV, SchneiderT, WilmesM, KornerC, TossiA, et al. (2010) Human beta-defensin 3 inhibits cell wall biosynthesis in Staphylococci. Infect Immun 78: 2793–2800.

20. SchmittP, WilmesM, PugniereM, AumelasA, BachereE, et al. (2010) Insight into invertebrate defensin mechanism of action: oyster defensins inhibit peptidoglycan biosynthesis by binding to lipid II. J Biol Chem 285: 29208–29216.

21. WuZ, EricksenB, TuckerK, LubkowskiJ, LuW (2004) Synthesis and characterization of human alpha-defensins 4–6. J Pept Res 64: 118–125.

22. WuZ, PowellR, LuW (2003) Productive folding of human neutrophil alpha-defensins in vitro without the pro-peptide. J Am Chem Soc 125: 2402–2403.

23. PaceCN, VajdosF, FeeL, GrimsleyG, GrayT (1995) How to measure and predict the molar absorption coefficient of a protein. Protein Sci 4: 2411–2423.

24. WiedemannI, BreukinkE, van KraaijC, KuipersOP, BierbaumG, et al. (2001) Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J Biol Chem 276: 1772–1779.

25. BreukinkE, van HeusdenHE, VollmerhausPJ, SwiezewskaE, BrunnerL, et al. (2003) Lipid II is an intrinsic component of the pore induced by nisin in bacterial membranes. J Biol Chem 278: 19898–19903.

26. EricksenB, WuZ, LuW, LehrerRI (2005) Antibacterial activity and specificity of the six human {alpha}-defensins. Antimicrob Agents Chemother 49: 269–275.

27. CLSI (2009) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Approved Standard, 8th edition.

28. DominguezC, BoelensR, BonvinAM (2003) HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. J Am Chem Soc 125: 1731–1737.

29. de VriesSJ, van DijkAD, KrzeminskiM, van DijkM, ThureauA, et al. (2007) HADDOCK versus HADDOCK: new features and performance of HADDOCK2.0 on the CAPRI targets. Proteins 69: 726–733.

30. HsuST, BreukinkE, TischenkoE, LuttersMA, de KruijffB, et al. (2004) The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nat Struct Mol Biol 11: 963–967.

31. LichtensteinSJ, DorfmanM, KennedyR, StromanD (2006) Controlling contagious bacterial conjunctivitis. J Pediatr Ophthalmol Strabismus 43: 19–26.

32. BrownRD, MartinYC (1997) The Information Content of 2D and 3D Structural Descriptors Relevant to Ligand-Receptor Binding. Journal of Chemical Information and Computer Sciences 37: 1–9.

33. XueL, GoddenJW, StahuraFL, BajorathJ (2003) Design and Evaluation of a Molecular Fingerprint Involving the Transformation of Property Descriptor Values into a Binary Classification Scheme. Journal of Chemical Information and Computer Sciences 43: 1151–1157.

34. HalgrenTA (1996) Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. Journal of Computational Chemistry 17: 490–519.

35. WillettP, BarnardJM, DownsGM (1998) Chemical Similarity Searching. Journal of Chemical Information and Computer Sciences 38: 983–996.

36. LipinskiCA, LombardoF, DominyBW, FeeneyPJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced drug delivery reviews 46: 3–26.

37. HopeMJ, BallyMB, WebbG, CullisPR (1985) Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochimica et biophysica acta 812: 55–65.

38. StasiukM, JarominA, KozubekA (2004) The effect of merulinic acid on biomembranes. Biochimica et biophysica acta 1667: 215–221.

39. BrooksBR, BrooksCLIII, MackerellADJr, NilssonL, PetrellaRJ, et al. (2009) CHARMM: the biomolecular simulation program. Journal of Computational Chemistry 30: 1545–1614.

40. MacKerellAD, BashfordD, Bellott, DunbrackRL, EvanseckJD, et al. (1998) All-Atom Empirical Potential for Molecular Modeling and Dynamics Studies of Proteins?? Journal of Physical Chemistry B 102: 3586–3616.

41. BestRB, ZhuX, ShimJ, LopesPEM, MittalJ, et al. (2012) Optimization of the Additive CHARMM All-Atom Protein Force Field Targeting Improved Sampling of the Backbone φ, ψ and Side-Chain χ1and χ2Dihedral Angles. Journal of Chemical Theory and Computation 8: 3257–3273.

42. GuvenchO, MallajosyulaSS, RamanEP, HatcherE, VanommeslaegheK, et al. (2011) CHARMM additive all-atom force field for carbohydrate derivatives and its utility in polysaccharide and carbohydrate-protein modeling. J Chem Theory Comput 7: 3162–3180.

43. MallajosyulaSS, GuvenchO, HatcherE, MacKerellAD (2011) CHARMM Additive All-Atom Force Field for Phosphate and Sulfate Linked to Carbohydrates. Journal of Chemical Theory and Computation 8: 759–776.

44. VanommeslaegheK, HatcherE, AcharyaC, KunduS, ZhongS, et al. (2010) CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. Journal of Computational Chemistry 31: 671–690.

45. JorgensenWL, ChandrasekharJ, MaduraJD, ImpeyRW, KleinML (1983) Comparison of Simple Potential Functions for Simulating Liquid Water. Journal of Chemical Physics 79: 926–935.

46. FellerSE, PastorRW, RojnuckarinA, BoguszS, BrooksBR (1996) Effect of electrostatic force truncation on interfacial and transport properties of water. Journal of Physical Chemistry 100: 17011–17020.

47. WeiG, de LeeuwE, PazgierM, YuanW, ZouG, et al. (2009) Through the looking glass, mechanistic insights from enantiomeric human defensins. J Biol Chem 284: 29180–29192.

48. WeiG, de LeeuwE, PazgierM, YuanW, ZouG, et al. (2009) Through the looking glass, mechanistic insights from enantiomeric human defensins. The Journal of biological chemistry 284: 29180–29192.

49. HsuST, BreukinkE, TischenkoE, LuttersMA, de KruijffB, et al. (2004) The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nature structural & molecular biology 11: 963–967.

50. WeiG, PazgierM, de LeeuwE, RajabiM, LiJ, et al. (2010) Trp-26 imparts functional versatility to human alpha-defensin HNP1. J Biol Chem 285: 16275–16285.

51. MaciasAT, MiaMY, XiaG, HayashiJ, MacKerellADJr (2005) Lead validation and SAR development via chemical similarity searching; application to compounds targeting the pY+3 site of the SH2 domain of p56lck. Journal of chemical information and modeling 45: 1759–1766.

52. ReyesN, SkinnerR, BentonBM, KrauseKM, SheltonJ, et al. (2006) Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. The Journal of antimicrobial chemotherapy 58: 462–465.

53. BrogdenKA (2005) Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 3: 238–250.

54. LienkampK, TewGN (2009) Synthetic mimics of antimicrobial peptides–a versatile ring-opening metathesis polymerization based platform for the synthesis of selective antibacterial and cell-penetrating polymers. Chemistry 15: 11784–11800.

55. PalermoEF, KurodaK (2010) Structural determinants of antimicrobial activity in polymers which mimic host defense peptides. Applied microbiology and biotechnology 87: 1605–1615.

56. SujathaS, PraharajI (2012) Glycopeptide resistance in gram-positive cocci: a review. Interdisciplinary perspectives on infectious diseases 2012: 781679.

57. IhiT, NakazatoM, MukaeH, MatsukuraS (1997) Elevated concentrations of human neutrophil peptides in plasma, blood, and body fluids from patients with infections. Clin Infect Dis 25: 1134–1140.

58. DaleBA, FredericksLP (2005) Antimicrobial peptides in the oral environment: expression and function in health and disease. Curr Issues Mol Biol 7: 119–133.

59. ColeAM, GanzT (2002) Antimicrobial peptides and proteins in the CF airway. Methods Mol Med 70: 447–464.

60. LaubeDM, YimS, RyanLK, KisichKO, DiamondG (2006) Antimicrobial peptides in the airway. Curr Top Microbiol Immunol 306: 153–182.

61. VollmerW (2008) Structural variation in the glycan strands of bacterial peptidoglycan. FEMS microbiology reviews 32: 287–306.

62. CLSI (2011) Performance Standards for Antimicrobial Susceptibility Testing; Twenty-first Informational Supplement. CLSI document M100-S21. www.clsi.org: Clinical and Laboratory Standards Institute.

63. HumphreyW, DalkeA, SchultenK (1996) VMD: visual molecular dynamics. Journal of molecular graphics 14: 33–38, 27–38.